# Prescription Drug User Fee Act Waivers, Reductions, and Refunds for Drug and Biological Products Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/prescription-drug-user-fee-act-waivers-reductions-and-refunds-for-drug-and-biological-products-guidance-for-industry/1a0bec17-eee8-4dda-9b43-4ca488355d7f

> FDA guidance document: Prescription Drug User Fee Act Waivers, Reductions, and Refunds for Drug and Biological Products Guidance for Industry. Issue date: October 17, 2019. Get complete insights and analysis.

---

## Details

- Title: Prescription Drug User Fee Act Waivers, Reductions, and Refunds for Drug and Biological Products Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2019-10-17
- Last Changed: 2020-05-15
- Docket Number: <a href="https://www.regulations.gov/docket/2019-22690 ">2019-22690 </a>

## Related Documents

- [Benefit-Risk Assessment for New Drug and Biological Products](https://www.globalkeysolutions.net/guidances/guidance-document/benefit-risk-assessment-for-new-drug-and-biological-products/90bf84f4-05cf-4617-b13d-bbb345349aed)
- [General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/general-clinical-pharmacology-considerations-for-neonatal-studies-for-drugs-and-biological-products-guidance-for-industry/0c57731e-55bc-4962-a619-54444aa22335)
- [Assessing User Fees Under the Prescription Drug User Fee Amendments of 2017 Guidance for Industry:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/assessing-user-fees-under-the-prescription-drug-user-fee-amendments-of-2017-guidance-for-industry-guidance-for-industry/0a6a0a53-093e-48c0-a832-4e3db4e95cd6)